Clinical Trial Update: Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating QM1114-DP for aesthetic improvement in moderate to severe glabellar frown lines and lateral canthal lines has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glabellar Frown Lines
• Lateral Canthal Lines

Drugs mentioned

• QM1114-DP

Snippet

Sponsor: Galderma R&D | Conditions: Glabellar Frown Lines, Canthal Lines | Phase 3 | Status: COMPLETED